期刊文献+

C35在乳腺癌中的表达及与Her2的相关性研究

Expression of C35 in Human Breast Carcinoma and Correlation with Her2
下载PDF
导出
摘要 目的探讨C35蛋白在乳腺癌中的表达及与Her2表达的相关性。方法应用免疫组化Envision二步法,检测58例乳腺癌组织和12例正常乳腺组织中C35和Her2的表达情况,并结合其临床病理特点进行分析。结果乳腺癌组织中C35蛋白的表达阳性率为62.07%(36/58),显著高于正常乳腺组织,差异有统计学意义(P<0.05),在正常乳腺组织C35蛋白不表达。C35蛋白表达与乳腺癌组织临床病理学特点存在相关性,随着乳腺癌组织的临床TNM分期、病理组织学分级的增加,C35蛋白阳性率显著升高,差异有统计学意义(P<0.05);乳腺癌组织C35蛋白表达与Her2蛋白的表达呈正相关(rs=0.348)。结论 C35参与乳腺癌的生长、侵袭和转移过程,可作为乳腺癌诊治的新靶点。 Objective To investigate the expression of C35 in human breast carcinoma and study the relationship between C35 and Her2. Methods The Envision immunohistochemical stain method was used to detect C35 and Her2 protein expressions in58 samples of breast carcinoma tissues and 12 cases of normal breast tissues. And clinical data were analyzed retrospectively. Results Positive rate of C35 was 62. 07%( 36 /58),and none of normal breast tissues was stained. The expression of C35 in human breast carcinoma was significantly higher than that in normal breast tissues( P〈0. 05),and the C35 protein in normal breast tissues showed no expression. The expression of C35 related dosely to clinical chara cteristics of breast cancer. The increased positive level of C35 was associated with advanled TNM stage and his tological grtade. There was a stable positive correlation between C35 and HER2( rs = 0. 348). Conclusion C35 participate the development,invasion and metastasis process of breast carcinoma. And can be used as a marker in diagnosis and a new target of in treatment of breast carcinoma.
出处 《四川医学》 CAS 2015年第7期923-926,共4页 Sichuan Medical Journal
基金 成都大学附属医院科研课题(编号:201302)
关键词 乳腺癌 C35 Her2 免疫组化 breast carcinoma C35 Her2 immunohistochemistry
  • 相关文献

参考文献10

  • 1Evans EE, Henn AD, Jonason A, et al. C35 (C17ort37) is a novel tumor biomark er abundantly expressed in breast cancer [ J ]. Mol Cancer Ther, 2006,5:2919- 2930.
  • 2Dasgupta S, Wasson LM, Rauniyar N, et al. Novel gene C17orf37 in 17ql 2 amplicon promotesmigration and invasion of prostate cancer cells [J]. Oncogene,2009,28(32) :2860-2872.
  • 3Benusiglio PR, Pharoah PD, Smith PL,et al. HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer[ J]. Br J Cancer,2006 ,95(12) :1689-1695.
  • 4乳腺癌HER2检测指南(2009版)[J].中华病理学杂志,2009,38(12):836-840. 被引量:192
  • 5Bang YJ,Van Cutsem E,Feyereislova A,et al. Trastuzumab in combi- nation with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA) : a phase3, open-label, randomised controlled trial [ J ]. Lan- cet,2010,376(9742) :687-697.
  • 6Han SW,Oh DY,Im SA,et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer[J]. Br J Cancer,2009,100(2) :298-304.
  • 7杨志慧,李桂梅,曹晓卉,梅佳,顾飞飞,殷正进.HER-2基因在乳腺癌中临床意义的探讨[J].临床与实验病理学杂志,2012,28(8):914-917. 被引量:18
  • 8刘莉,姜勇,李丽,刘都礼,李佽,杨建南,陈志英.HER2、COX-2及GST-π在胃癌中的表达及意义[J].现代肿瘤医学,2013,21(5):1066-1069. 被引量:4
  • 9Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of prima- ry breast can cer in HER2-positive women:a single technology apprais- al[J]. Health Technol Assess,2009,13 ( Suppll ) : 1-6.
  • 10Goel S, Chirgwin J, Francis P, et al. Rational use of trastuzumab in metastatic and locally advanced breast cancer:implications of recent re- search[J]. Breast,2011,20(2) :101-110.

二级参考文献29

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 2Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 4Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 5Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 6Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 7Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 8Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
  • 9Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.
  • 10Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER-2/ neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol,2002,118 (3) :408-417.

共引文献207

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部